REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Nature Genetics of a large genome-wide association study (GWAS) that used the company’s Proteograph® Product Suite to measure proteins at peptide-level resolution and map their genetic determinants. The study, led by Karsten Suhre, PhD, of Weill Cornell Medicine–Qatar, with collaborators from Harvard Medical School/Brigha ...

Core Insights - Clairity, Myriad Genetics, and MagView have formed a collaboration to enhance breast cancer risk assessment for women, aiming to fill a significant gap in identifying high-risk individuals without adding administrative burdens [1][2][7] Company Summaries Clairity - Clairity is an AI-powered precision health company that has developed Clairity Breast, the first FDA-authorized tool to estimate a woman's five-year breast cancer risk from a routine mammogram, focusing on prevention rather than detection [3][6] - The company aims to empower health systems and radiologists to act earlier in cancer care, potentially saving lives and reducing overall healthcare costs [3] Myriad Genetics - Myriad Genetics specializes in molecular diagnostic testing and precision medicine, offering tests that assess disease risk and guide treatment decisions, thereby improving patient care and reducing healthcare costs [4][6] - The integration of Myriad's MyRisk Hereditary Cancer Test with Clairity's AI-powered assessment is expected to provide clinicians with actionable insights for earlier and more personalized interventions against breast cancer [2][7] MagView - MagView is a leader in breast imaging workflow solutions, providing software that enhances mammography reporting and high-risk screening, utilized by over 2,500 facilities across the U.S. [5][6] - The Luminary Risk platform from MagView will integrate Clairity and Myriad's offerings, streamlining risk information capture and improving workflow efficiency for breast health management [2][5]

Core Insights - Palvella Therapeutics has announced QTORIN™ pitavastatin as a new product candidate for the treatment of disseminated superficial actinic porokeratosis (DSAP), a serious skin disease with no FDA-approved therapies available [1][3] - The company plans to initiate a Phase 2 clinical trial for QTORIN™ pitavastatin in the second half of 2026, following discussions with the FDA [1][3] Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases without FDA-approved treatments [5][6] - The company utilizes its patented QTORIN™ platform to develop novel topical product candidates, with QTORIN™ pitavastatin being the second product candidate in its pipeline [5][6] Disease Context - DSAP is characterized by persistent lesions that can lead to chronic skin integrity loss and has the potential to transform into squamous cell carcinoma [2] - There are over 50,000 diagnosed patients in the U.S. suffering from DSAP, highlighting a significant unmet medical need [2]

Core Insights - Century Therapeutics, Inc. is focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases and cancer [1][3] - Chad Cowan, Ph.D., the Chief Scientific Officer, will present at Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025 [1] - The company utilizes its proprietary Allo-Evasion™ technology to enhance immune evasion in its therapies, aiming to improve patient access and treatment outcomes [3] Company Overview - Century Therapeutics is a clinical-stage biotechnology firm listed on NASDAQ under the ticker IPSC [3] - The company is advancing a pipeline of iPSC-derived cell therapies, which are designed to address significant medical needs in autoimmune diseases and cancer [3] - The therapies are produced from the company's iPSC cell foundry, indicating a focus on innovative and scalable treatment solutions [3] Presentation Details - The presentation by Chad Cowan will take place at 12:20 p.m. ET in New York, NY [1] - A live webcast of the presentation will be accessible on the company's Investors page, with an archived replay available for at least 30 days [2]

Core Insights - Microbix Biosystems Inc. and EMQN CIC have launched a program to enhance the identification of patients with gene variants affecting the metabolism of Clopidogrel, a widely prescribed antiplatelet drug [1][2] Group 1: EQA Program Details - The new External Quality Assessment (EQA) program aims to ensure proficiency in Point-of-Care Tests (POCTs) that identify three gene variants of the Cytochrome P450 CYP2C19 enzyme, which are critical for determining appropriate Clopidogrel dosing [2][4] - Over 20% of individuals carry these gene variants, which can lead to either overdosing or underdosing of Clopidogrel, posing significant health risks [2][3] Group 2: Market Context - Clopidogrel is prescribed to over 15 million patients annually in the U.S. alone, indicating a substantial market for pharmacogenomic testing to optimize treatment and minimize risks associated with improper dosing [3] - The EQA program will provide participants with three samples every two months, totaling 18 samples per year, to ensure ongoing accuracy in genetic testing [4] Group 3: Company Contributions - Microbix is supplying quality assessment products (QAPs™) for the EQA program, which will assist in evaluating the accuracy of genetic tests and support safe prescription practices [4][5] - The collaboration with EMQN and Copan aims to enhance the quality of genetic testing, with Microbix expanding its role in the field of pharmacogenomics alongside its established presence in infectious diseases and oncology [5][7] Group 4: Company Background - Microbix Biosystems Inc. is a life sciences innovator with over 120 employees, generating revenues of approximately C$2.0 million or more per month, and is involved in manufacturing critical ingredients for the global diagnostics industry [7][8] - The company is ISO 9001 & 13485 accredited and has a presence in over 30 countries, supported by a network of international distributors [8]

Core Insights - Garetosmab is the first and only treatment to show significant reduction in both the number and volume of abnormal bone lesions in adults with fibrodysplasia ossificans progressiva (FOP) [1][2][6] - The Phase 3 OPTIMA trial met its primary endpoint, demonstrating a 90% or greater reduction in new heterotopic ossification (HO) lesions at 56 weeks [1][3][4] - The Independent Data Monitoring Committee recommended transitioning placebo patients to garetosmab, with U.S. regulatory submission planned for year-end 2025 [1][6] Trial Details - The OPTIMA trial was a global, multi-center, randomized, double-blind, placebo-controlled study involving 63 adults with FOP [2][9] - Participants received either placebo, 3 mg/kg garetosmab, or 10 mg/kg garetosmab every four weeks for 56 weeks [2][9] - Key secondary endpoints included a significant reduction in clinician-assessed flare-ups, with an 89% reduction in the 10 mg/kg group compared to placebo [4][5] Efficacy Results - At 56 weeks, the total number of new HO lesions was reduced by 94% in the 3 mg/kg group and 90% in the 10 mg/kg group compared to placebo [4][5] - The mean total volume of new HO lesions showed a reduction of 99% in both garetosmab treatment arms compared to placebo [4][5] Safety Profile - There were no discontinuations in the garetosmab treatment arms, with one discontinuation in the placebo arm due to an ovarian cyst [5] - A dose-dependent increase in skin and soft tissue infections was observed, but no serious bleeding events were reported [5] - Serious treatment-emergent adverse events occurred in a small number of patients across all treatment groups, with no deaths reported [5] Future Plans - A Phase 3 trial of garetosmab in adolescents and children with FOP, named OPTIMA 2, is planned to begin next year [6][11] - Global regulatory submissions for garetosmab are slated for 2026 following the U.S. submission [6]

Core Viewpoint - The article emphasizes the importance of efficient and reliable protein transfer techniques in Western Blotting, highlighting the challenges faced in traditional methods and introducing innovative solutions to enhance laboratory efficiency [1][24]. Summary by Sections Protein Transfer Challenges - Common issues in protein transfer include faint bands due to improper transfer time, high background noise from inadequate membrane handling, and inconsistent results caused by aging transfer equipment [3][4]. - These problems can lead to increased experimental repetition, wasted samples and reagents, and potential misinterpretation of results, ultimately affecting research progress [4]. Protein Transfer Methods - The article outlines three main types of protein transfer methods: wet transfer, semi-dry transfer, and dry transfer, each with its own advantages and limitations [5][6][10][14]. Wet Transfer - Wet transfer is a traditional method that requires a specific assembly order and is time-consuming, typically taking at least one hour [6][7]. - It is suitable for a wide range of protein sizes and complex samples but involves the use of toxic reagents, increasing laboratory waste [7]. Semi-Dry Transfer - Semi-dry transfer reduces transfer time to about 10 minutes but has limitations in transfer efficiency for large and small proteins [10][11]. - It requires careful control of experimental conditions and may necessitate additional optimization for different samples [11]. Dry Transfer - Dry transfer utilizes specialized transfer membranes and is faster but incurs higher long-term costs due to the price of consumables [14][15]. - It is sensitive to protein characteristics, making it less effective for extreme molecular weights [15]. Considerations for Protein Transfer - The choice of transfer method should be based on the specific requirements of the experiment, such as protein size and sample complexity [18]. - Proper preparation of the gel and membrane, as well as the use of fresh transfer buffer, are critical for successful protein transfer [19][21]. Innovations in Protein Transfer - The introduction of the eBlot™ rapid wet transfer system by Kingsray addresses traditional wet transfer issues, combining stability and speed to achieve efficient protein transfer in 5-15 minutes [24][25]. - The system is designed to enhance laboratory efficiency while maintaining high transfer quality, making it a valuable tool for researchers [24]. Promotional Activities - Kingsray is currently running a "trade-in" program for upgrading to the eBlot™ system, offering discounts based on the condition of old equipment and providing additional support for users [26][28].

Core Insights - Ionis Pharmaceuticals reported strong second-quarter results with adjusted earnings of 85 cents, a significant improvement from an adjusted loss of $35 million a year ago, and beating analysts' expectations of a 52-cent loss [1] - Revenue for the first quarter of 2025 increased by 10% to $132 million, surpassing the consensus estimate of $125.32 million, driven by higher commercial revenue [1] Revenue Performance - Ionis' revenues more than doubled to $452 million, exceeding the consensus of $282.95 million, primarily due to the successful launch of Tryngolza and increased royalty and R&D revenues [2] - Tryngolza generated net product sales of $19 million in the second quarter of 2025 and $26 million in the first half of 2025 [2] Product Developments - Tryngolza received a positive opinion from the Committee for Medicinal Products for Human Use, with a European Commission decision expected by Q4 2025 [3] - Wainua generated sales of $44 million in the second quarter of 2025, resulting in royalty revenue of $10 million [3] - Spinraza generated global sales of $393 million, leading to royalty revenue of $54 million [4] Financial Guidance - Ionis raised its fiscal 2025 sales guidance from $725 million-$750 million to $825 million-$850 million, compared to the consensus estimate of $754.67 million [6] - The company expects a 2025 adjusted operating loss of $300 million-$325 million, an improvement from previous guidance of less than $375 million [7] Market Reaction - Following the announcement, Ionis stock rose by 5.23% to $43.65 [7]

Group 1 - Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) has experienced a significant increase of approximately 28% since being rated as a "Buy" in February 2025 [1] - The focus of the analysis is on the company's position in the genetic obesity market, highlighting its potential for growth and investment opportunities [1] - The author emphasizes the importance of learning from both investment successes and failures, indicating a long-term commitment to research and analysis in the healthcare sector [1] Group 2 - The article reflects a personal investment in Rhythm Pharmaceuticals, indicating a beneficial long position in the shares [2] - The author expresses a commitment to sharing insights and experiences related to investing, particularly in healthcare stocks, which may provide valuable context for potential investors [1][2] - The analysis is based on years of focused research, suggesting a depth of knowledge regarding the company's operations and market dynamics [1]

Core Viewpoint - Regeneron Pharmaceuticals is acquiring bankrupt genomics firm 23andMe for $256 million, aiming to utilize its extensive DNA database while committing to ethical standards in data privacy [1][2][4]. Company Overview - 23andMe, once valued at $6 billion, filed for bankruptcy in March 2025 due to declining consumer interest and a significant data breach that affected millions [3]. - The acquisition is seen as a strategic move for Regeneron to enhance its genomic-driven drug discovery processes using 23andMe's database of over 15 million DNA samples [2][3]. Data Privacy Commitments - Regeneron has pledged to adhere to 23andMe's existing privacy guidelines and relevant data protection regulations, ensuring that personal data will not be used for research without explicit consent [4][5]. - An independent overseer will evaluate the deal's impact on consumer privacy, with a report due to the bankruptcy court in June [4]. Regulatory and Ethical Concerns - The acquisition has raised concerns among privacy advocates regarding the handling of genetic information, especially in light of past data breaches [4][10]. - U.S. lawmakers are monitoring the situation, worried that genetic data could be sold to entities with different ethical standards [10]. Future Implications - The deal highlights broader questions about ownership and usage of personal genetic data, emphasizing the potential risks associated with sharing such information [13][14]. - As the acquisition moves toward finalization in the third quarter of 2025, the fundamental question remains whether the benefits of contributing to medical research outweigh the privacy risks [14][15].